Lund AB - Search Results

1

Increased hepatic glucagon sensitivity in totally pancreatectomised patients.

Rix I, Lund AB, Garvey LF, Hansen CP, Chabanova E, Hartmann B, Holst JJ, Vilsbøll T, Van Hall G, Knop FK. Rix I, et al. Among authors: lund ab. Eur J Endocrinol. 2024 Jun 5;190(6):446-457. doi: 10.1093/ejendo/lvae054. Eur J Endocrinol. 2024. PMID: 38781444

2

The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency.

Knop FK, Vilsbøll T, Lund A, Krarup T, Holst JJ, Hornum M. Knop FK, et al. JOP. 2010 Sep 6;11(5):489-91. JOP. 2010. PMID: 20818126 Free article. Clinical Trial. No abstract available.

3

Impaired regulation of the incretin effect in patients with type 2 diabetes.

Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsbøll T. Bagger JI, et al. J Clin Endocrinol Metab. 2011 Mar;96(3):737-45. doi: 10.1210/jc.2010-2435. Epub 2011 Jan 20. J Clin Endocrinol Metab. 2011. PMID: 21252240

4

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.

Lund A, Vilsbøll T, Bagger JI, Holst JJ, Knop FK. Lund A, et al. Am J Physiol Endocrinol Metab. 2011 Jun;300(6):E1038-46. doi: 10.1152/ajpendo.00665.2010. Epub 2011 Mar 8. Am J Physiol Endocrinol Metab. 2011. PMID: 21386059 Free article.

5

Regulation of glucagon secretion by incretins.

Holst JJ, Christensen M, Lund A, de Heer J, Svendsen B, Kielgast U, Knop FK. Holst JJ, et al. Diabetes Obes Metab. 2011 Oct;13 Suppl 1:89-94. doi: 10.1111/j.1463-1326.2011.01452.x. Diabetes Obes Metab. 2011. PMID: 21824261 Review.

6

Emerging GLP-1 receptor agonists.

Lund A, Knop FK, Vilsbøll T. Lund A, et al. Expert Opin Emerg Drugs. 2011 Dec;16(4):607-18. doi: 10.1517/14728214.2011.616493. Epub 2011 Sep 9. Expert Opin Emerg Drugs. 2011. PMID: 21905764 Review.

7

Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea.

Lund A, Knop FK. Lund A, et al. Curr Med Res Opin. 2012 May;28(5):731-6. doi: 10.1185/03007995.2012.681639. Epub 2012 Apr 24. Curr Med Res Opin. 2012. PMID: 22462528

8

Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetes.

Hansen M, Nielsen AR, Vilsbøll T, Lund A, Krarup T, Knop FK, Vestergaard H. Hansen M, et al. Pancreas. 2012 Nov;41(8):1316-8. doi: 10.1097/MPA.0b013e31824d9b93. Pancreas. 2012. PMID: 22647735

9

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.

Lund A, Knop FK, Vilsbøll T. Lund A, et al. Eur J Intern Med. 2014 Jun;25(5):407-14. doi: 10.1016/j.ejim.2014.03.005. Epub 2014 Mar 30. Eur J Intern Med. 2014. PMID: 24694879 Review.

10

Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals.

Bagger JI, Knop FK, Lund A, Holst JJ, Vilsbøll T. Bagger JI, et al. Diabetologia. 2014 Aug;57(8):1720-5. doi: 10.1007/s00125-014-3264-2. Epub 2014 May 31. Diabetologia. 2014. PMID: 24879388

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters